Who are HBV-MPL 208129's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Tat, HD Vaccine, Mycobacterium Vaccae for Injection, TEP, V7, GC3110A(Trivalent).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/hbv-mpl-208129.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

HBV-MPL 208129 — Competitive Intelligence Brief

HBV-MPL 208129 (HBV-MPL 208129) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Therapeutic vaccine. Area: Immunology / Virology.

phase 3 Therapeutic vaccine HBV antigens; TLR4 (via MPL adjuvant) Immunology / Virology Biologic Live · refreshed every 30 min

Target snapshot

HBV-MPL 208129 (HBV-MPL 208129) — GlaxoSmithKline. HBV-MPL 208129 is a therapeutic vaccine that combines hepatitis B virus (HBV) antigens with MPL (monophosphoryl lipid A) adjuvant to stimulate immune responses against chronic HBV infection.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
HBV-MPL 208129 TARGET	HBV-MPL 208129	GlaxoSmithKline	phase 3	Therapeutic vaccine	HBV antigens; TLR4 (via MPL adjuvant)
Tat	Tat	Barbara Ensoli, MD	marketed	Therapeutic vaccine	HIV Tat protein
HD Vaccine	HD Vaccine	Insight Therapeutics, LLC	marketed	Therapeutic vaccine	Huntingtin protein (HTT)
Mycobacterium Vaccae for Injection	Mycobacterium Vaccae for Injection	Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.	marketed	Immunotherapeutic vaccine
TEP	TEP	Immungenetics AG	marketed	Therapeutic vaccine
V7	V7	Immunitor LLC	phase 3	Therapeutic vaccine
GC3110A(Trivalent)	GC3110A(Trivalent)	Green Cross Corporation	phase 3	Therapeutic vaccine

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Therapeutic vaccine class)

Immunitor LLC · 3 drugs in this class
GlaxoSmithKline · 2 drugs in this class
Henogen · 2 drugs in this class
SK Chemicals Co., Ltd. · 2 drugs in this class
Merck Sharp & Dohme LLC · 2 drugs in this class
Cytos Biotechnology AG · 2 drugs in this class
Clinical Research Organization, Dhaka, Bangladesh · 1 drug in this class
Barbara Ensoli, MD · 1 drug in this class
Green Cross Corporation · 1 drug in this class
Chiang Mai University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). HBV-MPL 208129 — Competitive Intelligence Brief. https://druglandscape.com/ci/hbv-mpl-208129. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab